NEW YORK – Artelo Biosciences on Friday said it was accepted into the UK's Alderley Park Oncology Development Program, which is supporting and funding the development of its FABP5 inhibitor.
The Alderley Park Oncology Development Program advises and funds companies developing innovative oncology products. It is funded by Innovate UK and Cancer Research UK, and supported by pharma companies including AstraZeneca, Johnson & Johnson, GlaxoSmithKline, and Roche.
The La Jolla, California-based company is developing a FABP5 inhibitor, ART26.12, which is still in preclinical studies. ART26.12 has been previously studied in hormonally driven cancers such as breast, prostate, and cervical carcinomas, Artelo CSO Andy Yates said in a statement, but research suggests it may be effective in a wider range of cancers.
"It has recently been shown that FABP5 was detectable in saliva and breath condensate for certain tumor types, including multiple myeloma and lung cancer, suggesting that these readily available and non-invasive biofluids could be used to measure FABP5 expression as a predictive biomarker of both disease prognosis and also response to FABP5 inhibition in cancers with high unmet need," Yates said.
Last year, Artelo and Stony Brook University also received a $4.2 million grant from the National Cancer Institute to advance the FABP5 program.